GSK Pharma Q1 FY27 results: Revenue Rs 924 Cr, PAT Rs 253 Cr, up 24% YoY
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GSK Pharma Q1 FY27 standalone revenue from operations grew about 15% YoY to Rs 924 Cr, with PAT up nearly 24% at Rs 253 Cr. PBT was Rs 338 Cr versus Rs 279 Cr last year. EPS stood at Rs 14.95 versus Rs 12.08. Other income of Rs 62 Cr included Rs 18 Cr dividend from subsidiary Biddle Sawyer. Auditor Deloitte issued a clean limited review. Board appointed Ms Karine J F Natland as Non-Executive Director and re-appointed MD Bhushan Akshikar for 2 years from Dec 2026. Mr Subesh Williams stepped down.
Strong quarter with double-digit revenue and earnings growth. Board continuity maintained, neutral on management change.